1. [Immunotherapy for Alzheimer's disease].
- Author
-
Falkentoft AC and Hasselbalch SG
- Subjects
- Alzheimer Disease immunology, Alzheimer Disease metabolism, Amyloid beta-Peptides antagonists & inhibitors, Amyloid beta-Peptides immunology, Amyloid beta-Peptides metabolism, Antibodies, Monoclonal, Humanized therapeutic use, Humans, Immunization, Passive, Immunoglobulins, Intravenous therapeutic use, Alzheimer Disease drug therapy, Antibodies, Monoclonal therapeutic use
- Abstract
Passive anti-beta-amyloid (Aß) immunotherapy has been shown to clear brain Aß deposits. Results from phase III clinical trials in mild-to-moderate Alzheimer's disease (AD) patients with two monoclonal antibodies bapineuzumab and solanezumab and intravenous immunoglobulin have been disappointing. Subsequent analysis of pooled data from both phase III trials with solanezumab showed a reduction in cognitive decline in patients with mild AD. Solanezumab and new monoclonal antibodies are being tested in patients with prodromal and preclinical AD in search for a disease-modifying treatment.
- Published
- 2016